NURS 5334 QUIZ 1: CORE PK/PD PRINCIPLES & CELL WALL
INHIBITORS (PART 1) QUESTIONS AND CORRECT
ANSWERS PLUS RATIONALE NEW UPDATE 2026-2027 UTA
99 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply pharmacokinetic parameters (Vd, clearance, half-life, bioavailability, protein binding) to predict drug
disposition and dosing adjustments in complex clinical scenarios
2 Differentiate pharmacodynamic models (time-dependent vs concentration-dependent killing,
post-antibiotic effect, therapeutic index) and link them to antimicrobial dosing strategies
3 Analyze mechanisms of beta-lactam and glycopeptide action and resistance (PBPs, beta-lactamases,
MRSA, VRE) to select appropriate therapy and monitoring
4 Integrate PK/PD indices (T>MIC, AUC/MIC, Cmax/MIC) to optimize efficacy and minimize toxicity for cell
wall inhibitors
5 Evaluate adverse drug reactions, drug interactions, and monitoring parameters specific to cell wall
inhibitor antibiotics using evidence-based rationale
6 NURS 5334 Quiz 1
7 Core PK
8 PD Principles & Cell Wall Inhibitors
9 Questions and Correct Answers plus Rationale New Update 2026
10 2027 UTA
11 Foundations of Nursing Pharmacology - Pharmacokinetics, Pharmacodynamics, and Cell Wall Inhibitor
Antibacterials
12 Applied Nursing Pharmacology - Pharmacokinetics, Pharmacodynamics, and Cell Wall Inhibitor
Antibacterials
13 Advanced Nursing Pharmacology - Pharmacokinetics, Pharmacodynamics, and Cell Wall Inhibitor
Antibacterials
14 Nursing Pharmacology - Pharmacokinetics, Pharmacodynamics, and Cell Wall Inhibitor Antibacterials
Review
ABSTRACT
Page 1
,This study document brings together 99 carefully worded exam questions drawn from NURS 5334
Quiz 1: Core PK/PD Principles & Cell Wall Inhibitors (Part 1) Questions and Correct Answers plus
Rationale New Update 2026-2027 UTA, with the strongest emphasis placed on Apply
pharmacokinetic parameters (Vd, clearance, half-life, bioavailability, protein binding) to predict drug
disposition and dosing adjustments in complex clinical scenarios, Differentiate pharmacodynamic
models (time-dependent vs concentration-dependent killing, post-antibiotic effect, therapeutic
index) and link them to antimicrobial dosing strategies, Analyze mechanisms of beta-lactam and
glycopeptide action and resistance (PBPs, beta-lactamases, MRSA and VRE) to select appropriate
therapy and monitoring. Every item follows the wording style and level of reasoning you meet in the
real paper, and each one is paired with a clear rationale so the correct choice is never a guess.
Work through the set at your own pace, mark the questions that slow you down, then come back to
them until the reasoning feels automatic. Learners who revise this way walk into the exam room
recognising the pattern behind the questions instead of meeting them for the first time. Keep going
- steady, honest practice is what turns a difficult paper into a comfortable pass.
Q1 APPLY PHARMACOKINETIC PARAMETERS (VD, CLEARANCE, HALF-LIFE,
BIOAVAILABILITY, PROTEIN BINDING) TO PREDICT DRUG DISPOSITION AND DOSING
ADJUSTMENTS IN COMPLEX CLINICAL SCENARIOS
A patient with severe hypoalbuminemia (serum albumin 1.8 g/dL) is receiving a
highly protein-bound beta-lactam (95% bound). Which pharmacokinetic
consequence is most likely, and how should dosing be interpreted?
A. Total drug concentration falls, free fraction rises, and pharmacologic effect may increase
despite normal total levels. CORRECT
B. Total drug concentration rises, free fraction falls, and toxicity risk decreases.
C. Both free and total drug concentrations remain unchanged because protein binding is
saturated.
D. Volume of distribution decreases and half-life prolongs due to reduced binding sites.
RATIONALE: In hypoalbuminemia, fewer binding sites reduce the bound fraction, lowering total
drug concentration while increasing the free (active) fraction. Because only free drug is
pharmacologically active, effect can be enhanced and toxicity risk may rise even when total
levels appear normal. The other options incorrectly describe binding or distribution changes.
Page 2
,Q2 APPLY PHARMACOKINETIC PARAMETERS (VD, CLEARANCE, HALF-LIFE,
BIOAVAILABILITY, PROTEIN BINDING) TO PREDICT DRUG DISPOSITION AND DOSING
ADJUSTMENTS IN COMPLEX CLINICAL SCENARIOS
Which pharmacodynamic property best explains why beta-lactam antibiotics
require frequent or prolonged infusion dosing rather than large intermittent
boluses?
A. Concentration-dependent killing with a long post-antibiotic effect
B. Time-dependent killing with minimal post-antibiotic effect CORRECT
C. Concentration-dependent killing with a short post-antibiotic effect
D. Time-dependent killing with a long post-antibiotic effect
RATIONALE: Beta-lactams exhibit time-dependent killing, where efficacy correlates with the
duration that free drug concentration exceeds the MIC (T>MIC). They have minimal to no
post-antibiotic effect against most gram-negative organisms, so maintaining levels above MIC for
a large portion of the dosing interval is critical. Concentration-dependent killing and long PAE are
characteristic of aminoglycosides, not beta-lactams.
Q3 APPLY PHARMACOKINETIC PARAMETERS (VD, CLEARANCE, HALF-LIFE,
BIOAVAILABILITY, PROTEIN BINDING) TO PREDICT DRUG DISPOSITION AND DOSING
ADJUSTMENTS IN COMPLEX CLINICAL SCENARIOS
A patient is prescribed IV vancomycin for MRSA bacteremia. The AUC/MIC ratio is
the target pharmacodynamic index. Which monitoring strategy best reflects
current consensus guidelines to ensure efficacy and minimize nephrotoxicity?
A. Peak serum concentration 1 hour after infusion, targeting 30-40 mcg/mL
B. Trough serum concentration targeting 5-10 mcg/mL
C. AUC24/MIC ratio of 400-600 using Bayesian software or two serum levels CORRECT
D. Random serum level at any time, targeting 15-20 mcg/mL
RATIONALE: Current vancomycin guidelines recommend AUC24/MIC-guided dosing (target
400-600) for serious MRSA infections to maximize efficacy while reducing nephrotoxicity
compared with high trough-only monitoring. Trough-only targets (15-20 mcg/mL) are associated
with increased AKI and are no longer preferred when AUC monitoring is available. Peak levels
and random levels are not validated for vancomycin efficacy.
Page 3
, Q4 APPLY PHARMACOKINETIC PARAMETERS (VD, CLEARANCE, HALF-LIFE,
BIOAVAILABILITY, PROTEIN BINDING) TO PREDICT DRUG DISPOSITION AND DOSING
ADJUSTMENTS IN COMPLEX CLINICAL SCENARIOS
A patient with a beta-lactam allergy history is to receive aztreonam. Which
statement about cross-reactivity is most accurate?
A. Aztreonam cross-reacts significantly with penicillins due to shared beta-lactam ring.
B. Aztreonam has minimal cross-reactivity with penicillins but may cross-react with ceftazidime.
CORRECT
C. Aztreonam cross-reacts with all cephalosporins because of identical side chains.
D. Aztreonam is contraindicated in any patient with a cephalosporin allergy.
RATIONALE: Aztreonam is a monobactam with a unique side chain that rarely cross-reacts with
penicillins or most cephalosporins, except ceftazidime, which shares an identical R1 side chain.
Therefore, it can often be used safely in patients with penicillin allergy, but caution is needed if
ceftazidime allergy exists. The other options overstate cross-reactivity.
Q5 APPLY PHARMACOKINETIC PARAMETERS (VD, CLEARANCE, HALF-LIFE,
BIOAVAILABILITY, PROTEIN BINDING) TO PREDICT DRUG DISPOSITION AND DOSING
ADJUSTMENTS IN COMPLEX CLINICAL SCENARIOS
Which mechanism of resistance to vancomycin in Enterococcus faecium (VRE)
involves alteration of the drug's target?
A. Production of beta-lactamase
B. Modification of peptidoglycan precursors from D-Ala-D-Ala to D-Ala-D-Lac CORRECT
C. Efflux pump overexpression
D. Porin channel mutation
RATIONALE: Vancomycin resistance in VRE is primarily mediated by van gene clusters that alter
peptidoglycan precursors, replacing D-Ala-D-Ala with D-Ala-D-Lac or D-Ala-D-Ser, reducing
vancomycin binding affinity. Beta-lactamase production, efflux, and porin changes are
mechanisms for other antibiotics. This target alteration is the classic mechanism for vancomycin
resistance.
Page 4
INHIBITORS (PART 1) QUESTIONS AND CORRECT
ANSWERS PLUS RATIONALE NEW UPDATE 2026-2027 UTA
99 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply pharmacokinetic parameters (Vd, clearance, half-life, bioavailability, protein binding) to predict drug
disposition and dosing adjustments in complex clinical scenarios
2 Differentiate pharmacodynamic models (time-dependent vs concentration-dependent killing,
post-antibiotic effect, therapeutic index) and link them to antimicrobial dosing strategies
3 Analyze mechanisms of beta-lactam and glycopeptide action and resistance (PBPs, beta-lactamases,
MRSA, VRE) to select appropriate therapy and monitoring
4 Integrate PK/PD indices (T>MIC, AUC/MIC, Cmax/MIC) to optimize efficacy and minimize toxicity for cell
wall inhibitors
5 Evaluate adverse drug reactions, drug interactions, and monitoring parameters specific to cell wall
inhibitor antibiotics using evidence-based rationale
6 NURS 5334 Quiz 1
7 Core PK
8 PD Principles & Cell Wall Inhibitors
9 Questions and Correct Answers plus Rationale New Update 2026
10 2027 UTA
11 Foundations of Nursing Pharmacology - Pharmacokinetics, Pharmacodynamics, and Cell Wall Inhibitor
Antibacterials
12 Applied Nursing Pharmacology - Pharmacokinetics, Pharmacodynamics, and Cell Wall Inhibitor
Antibacterials
13 Advanced Nursing Pharmacology - Pharmacokinetics, Pharmacodynamics, and Cell Wall Inhibitor
Antibacterials
14 Nursing Pharmacology - Pharmacokinetics, Pharmacodynamics, and Cell Wall Inhibitor Antibacterials
Review
ABSTRACT
Page 1
,This study document brings together 99 carefully worded exam questions drawn from NURS 5334
Quiz 1: Core PK/PD Principles & Cell Wall Inhibitors (Part 1) Questions and Correct Answers plus
Rationale New Update 2026-2027 UTA, with the strongest emphasis placed on Apply
pharmacokinetic parameters (Vd, clearance, half-life, bioavailability, protein binding) to predict drug
disposition and dosing adjustments in complex clinical scenarios, Differentiate pharmacodynamic
models (time-dependent vs concentration-dependent killing, post-antibiotic effect, therapeutic
index) and link them to antimicrobial dosing strategies, Analyze mechanisms of beta-lactam and
glycopeptide action and resistance (PBPs, beta-lactamases, MRSA and VRE) to select appropriate
therapy and monitoring. Every item follows the wording style and level of reasoning you meet in the
real paper, and each one is paired with a clear rationale so the correct choice is never a guess.
Work through the set at your own pace, mark the questions that slow you down, then come back to
them until the reasoning feels automatic. Learners who revise this way walk into the exam room
recognising the pattern behind the questions instead of meeting them for the first time. Keep going
- steady, honest practice is what turns a difficult paper into a comfortable pass.
Q1 APPLY PHARMACOKINETIC PARAMETERS (VD, CLEARANCE, HALF-LIFE,
BIOAVAILABILITY, PROTEIN BINDING) TO PREDICT DRUG DISPOSITION AND DOSING
ADJUSTMENTS IN COMPLEX CLINICAL SCENARIOS
A patient with severe hypoalbuminemia (serum albumin 1.8 g/dL) is receiving a
highly protein-bound beta-lactam (95% bound). Which pharmacokinetic
consequence is most likely, and how should dosing be interpreted?
A. Total drug concentration falls, free fraction rises, and pharmacologic effect may increase
despite normal total levels. CORRECT
B. Total drug concentration rises, free fraction falls, and toxicity risk decreases.
C. Both free and total drug concentrations remain unchanged because protein binding is
saturated.
D. Volume of distribution decreases and half-life prolongs due to reduced binding sites.
RATIONALE: In hypoalbuminemia, fewer binding sites reduce the bound fraction, lowering total
drug concentration while increasing the free (active) fraction. Because only free drug is
pharmacologically active, effect can be enhanced and toxicity risk may rise even when total
levels appear normal. The other options incorrectly describe binding or distribution changes.
Page 2
,Q2 APPLY PHARMACOKINETIC PARAMETERS (VD, CLEARANCE, HALF-LIFE,
BIOAVAILABILITY, PROTEIN BINDING) TO PREDICT DRUG DISPOSITION AND DOSING
ADJUSTMENTS IN COMPLEX CLINICAL SCENARIOS
Which pharmacodynamic property best explains why beta-lactam antibiotics
require frequent or prolonged infusion dosing rather than large intermittent
boluses?
A. Concentration-dependent killing with a long post-antibiotic effect
B. Time-dependent killing with minimal post-antibiotic effect CORRECT
C. Concentration-dependent killing with a short post-antibiotic effect
D. Time-dependent killing with a long post-antibiotic effect
RATIONALE: Beta-lactams exhibit time-dependent killing, where efficacy correlates with the
duration that free drug concentration exceeds the MIC (T>MIC). They have minimal to no
post-antibiotic effect against most gram-negative organisms, so maintaining levels above MIC for
a large portion of the dosing interval is critical. Concentration-dependent killing and long PAE are
characteristic of aminoglycosides, not beta-lactams.
Q3 APPLY PHARMACOKINETIC PARAMETERS (VD, CLEARANCE, HALF-LIFE,
BIOAVAILABILITY, PROTEIN BINDING) TO PREDICT DRUG DISPOSITION AND DOSING
ADJUSTMENTS IN COMPLEX CLINICAL SCENARIOS
A patient is prescribed IV vancomycin for MRSA bacteremia. The AUC/MIC ratio is
the target pharmacodynamic index. Which monitoring strategy best reflects
current consensus guidelines to ensure efficacy and minimize nephrotoxicity?
A. Peak serum concentration 1 hour after infusion, targeting 30-40 mcg/mL
B. Trough serum concentration targeting 5-10 mcg/mL
C. AUC24/MIC ratio of 400-600 using Bayesian software or two serum levels CORRECT
D. Random serum level at any time, targeting 15-20 mcg/mL
RATIONALE: Current vancomycin guidelines recommend AUC24/MIC-guided dosing (target
400-600) for serious MRSA infections to maximize efficacy while reducing nephrotoxicity
compared with high trough-only monitoring. Trough-only targets (15-20 mcg/mL) are associated
with increased AKI and are no longer preferred when AUC monitoring is available. Peak levels
and random levels are not validated for vancomycin efficacy.
Page 3
, Q4 APPLY PHARMACOKINETIC PARAMETERS (VD, CLEARANCE, HALF-LIFE,
BIOAVAILABILITY, PROTEIN BINDING) TO PREDICT DRUG DISPOSITION AND DOSING
ADJUSTMENTS IN COMPLEX CLINICAL SCENARIOS
A patient with a beta-lactam allergy history is to receive aztreonam. Which
statement about cross-reactivity is most accurate?
A. Aztreonam cross-reacts significantly with penicillins due to shared beta-lactam ring.
B. Aztreonam has minimal cross-reactivity with penicillins but may cross-react with ceftazidime.
CORRECT
C. Aztreonam cross-reacts with all cephalosporins because of identical side chains.
D. Aztreonam is contraindicated in any patient with a cephalosporin allergy.
RATIONALE: Aztreonam is a monobactam with a unique side chain that rarely cross-reacts with
penicillins or most cephalosporins, except ceftazidime, which shares an identical R1 side chain.
Therefore, it can often be used safely in patients with penicillin allergy, but caution is needed if
ceftazidime allergy exists. The other options overstate cross-reactivity.
Q5 APPLY PHARMACOKINETIC PARAMETERS (VD, CLEARANCE, HALF-LIFE,
BIOAVAILABILITY, PROTEIN BINDING) TO PREDICT DRUG DISPOSITION AND DOSING
ADJUSTMENTS IN COMPLEX CLINICAL SCENARIOS
Which mechanism of resistance to vancomycin in Enterococcus faecium (VRE)
involves alteration of the drug's target?
A. Production of beta-lactamase
B. Modification of peptidoglycan precursors from D-Ala-D-Ala to D-Ala-D-Lac CORRECT
C. Efflux pump overexpression
D. Porin channel mutation
RATIONALE: Vancomycin resistance in VRE is primarily mediated by van gene clusters that alter
peptidoglycan precursors, replacing D-Ala-D-Ala with D-Ala-D-Lac or D-Ala-D-Ser, reducing
vancomycin binding affinity. Beta-lactamase production, efflux, and porin changes are
mechanisms for other antibiotics. This target alteration is the classic mechanism for vancomycin
resistance.
Page 4
